Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 29, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

October 12, 2022

Conditions
Trypanosomiasis, AfricanSleeping SicknessTrypanosoma Brucei Rhodesiense; Infection
Interventions
DRUG

Fexinidazole

Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)

Trial Locations (2)

PO Box 225

Rumphi District Hospital, Rumphi

PO Box 650

Lwala Hospital, Lwala

All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

Drugs for Neglected Diseases

OTHER

NCT03974178 - Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense | Biotech Hunter | Biotech Hunter